The global AI and healthcare community gather in Switzerland

According to a report by MarketsandMarkets, the AI in Healthcare Market is projected to grow from $14.6 Billion in 2023 to $102.7 Billion by 2028. 

The summit will feature stories of AI in action, use cases of AI application from around the globe, deep-dive tech talks, innovation insights, and hands-on workshops. Themes this year include impact of generative AI and LLMs on the healthcare industry, global health equity, healthy cities, product development, potential benefits of aggregating scientific data, latest regulatory challenges, personalised data insights and interoperable solutions, cybersecurity in healthcare, the impact of multi-modular data, and the future of healthcare with Big Tech and AI.

A strong player in advancing health equity through data-driven population health approaches, the Novartis Foundation joins as Headline Partner for the fifth consecutive year.

Some of the most influential minds in AI and healthcare will take to the stage including Dr Ann Aerts, Head, Novartis Foundation; Dr Zenobia Brown, Associate CMO, Medical Director, Northwell Health Solutions Population Health Management, Northwell Health; Dr Aisha Rahim, Medical Executive and Director, Johns Hopkins HealthCare; Dr Sujoy Kar, Chief Medical Information Officer and Vice President, Apollo Hospitals; Jiangtao Wang, Associate Professor of Health Data Science, Research Centre for Intelligent Healthcare, Coventry University; Peter Speyer, Head of Data, Analytics and AI, Novartis Foundation. 

Sarah Porter, CEO and Founder of InspiredMinds, says: “IntelligentHealth is unique in the fact that it brings together scientists making exponential breakthroughs with world leading technologists. By applying tools such as AI and ML on chemistry, drug discovery and on major medical advances, we can reduce pressures on human labour by harnessing the speed of machine labour – the end effect of which will improve clinical outcomes and patient care. We are poised at a unique time in history where such breakthroughs are beyond the pace of those ever seen before – Intelligent Health will showcase the best of them and allow the opportunity for us to moonshot many more.”

Basel is home to more than 700 life sciences companies, 1,000 research groups and an emerging health tech sector. There is also a high number of pharmaceutical companies with HQ’s in Switzerland and, specifically, Basel. 

One reason for healthcare companies to consider the Basel Area is the DayOne Accelerator, Switzerland’s digital health and med tech accelerator – one of the biggest in Europe, which helps companies create commercial ties with the leading life sciences industry that they wouldn’t be able to do or find elsewhere.

It is predicted that the Basel Area will become a hub for the so-called Fourth Industrial Revolution, which will combine technology with traditional pharmaceutical and life sciences approaches to healthcare.